Aditxt ADTX

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.00 (+3.88%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Aditxt (ADTX)
    Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $0.0515

    • Market Cap

      $4.06 Million

    • Price-Earnings Ratio

      -0.00

    • Total Outstanding Shares

      78.89 Million Shares

    • Total Employees

      47

    • Dividend

      No dividend

    • IPO Date

      June 30, 2020

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      737 n. fifth street, suite 200, Richmond, VA, 23219

    • Homepage

      https://www.aditxt.com

    Historical Stock Splits

    If you bought 80,000 shares of ADTX before September 14, 2022, you'd have 1 share today.
    Execution DateSplit Amount
    October 2, 20241-for-40 (Reverse Split)
    August 18, 20231-for-40 (Reverse Split)
    September 14, 20221-for-50 (Reverse Split)

    Cash Flow Statement

    April 1, 2023 to March 31, 2024
    MetricValue
    Net Cash Flow From Investing Activities$-927
    Net Cash Flow From Operating Activities, Continuing$-20.59 Million
    Net Cash Flow$-205,407
    Net Cash Flow From Investing Activities, Continuing$-927
    Net Cash Flow From Financing Activities$20.38 Million
    Net Cash Flow From Financing Activities, Continuing$20.38 Million

    Income Statement

    April 1, 2023 to March 31, 2024
    MetricValue
    Preferred Stock Dividends And Other Adjustments$319,871
    Cost Of Revenue$644,326
    Net Income/Loss$-84.10 Million
    Basic Average Shares$8.14 Million
    Other Operating Expenses$17.85 Million
    Research and Development$13.83 Million

    Comprehensive Income

    April 1, 2023 to March 31, 2024
    MetricValue
    Comprehensive Income/Loss$-84.10 Million
    Other Comprehensive Income/Loss$0
    Comprehensive Income/Loss Attributable To Parent$-84.10 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

    Balance Sheet

    April 1, 2023 to March 31, 2024
    MetricValue
    Equity$9.78 Million
    Noncurrent Liabilities$891,747
    Current Assets$1.60 Million
    Fixed Assets$2.02 Million
    Current Liabilities$17.30 Million
    Other Non-current Assets$24.35 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ADTX from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.